Thetis Pharmaceuticals Announces Poster Presentation at 2023 AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
Poster to highlight preclinical data showing that TP-317 drives efficacy in solid tumors by engaging innate and adaptive anti tumor immunity in the tumor microenvironment (TME)
ESSEX, CT – (October 4, 2023) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing a first-in-class small molecule BLT1 agonist to treat cancer and chronic inflammatory diseases, today announced that an abstract has been selected for presentation at the upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023 in Boston, MA. The poster to be presented at the conference in Poster Session A on Thursday, October 12, 12:30 pm-4:00 pm (Level 2, Exhibit Hall D),can be viewed at this link.
"In established syngeneic murine solid tumors TP 317 broadly modulates innate and adaptive immune cell compartments in the TME, consistent with resetting the immunogenic tone and favoring anti tumor immunity. RNA sequencing reveals that TP 317 upregulates MHC I/MHC II antigen presenting pathways both within the myeloid immune compartment and tumor cells, said John Parkinson, Chief Scientific Officer of Thetis Pharmaceuticals, “TP-317 is a first-in-class, small molecule drug with a novel and highly differentiated myeloid-directed mechanism of action that has transformational potential for the treatment of high unmet medical need solid tumors such as metastatic colorectal cancer and refractory NSCLC .”
About Thetis Pharmaceuticals
Thetis is a pharmaceutical company focused on developing innovative treatments for chronic inflammatory diseases and cancer. Its lead candidate, TP-317, is a first-in-class oral RvE1 drug candidate that targets the LTB4-BLT1 pathway to harness the body’s natural ability to resolve disease and restore immune homeostasis. Thetis is backed by private investors, the National Institutes of Health (NIH), and prominent philanthropic organizations such as the Helmsley Charitable Trust, Crohn's & Colitis Foundation, and Kenneth Rainin Foundation.
Contact Information
Tracy Lessor
TLOW Communications, LLC
617-519-9827
tracy@tlowcommunications.com